Where Will Rani Therapeutics Holdings Inc (RANI) Stock Go Next After It Has Gained 9.57% in a Week?

The market has been high on Rani Therapeutics Holdings Inc (RANI) stock recently. RANI gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Rani Therapeutics Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on RANI!

See Full RANI Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With RANI Stock Today?

Rani Therapeutics Holdings Inc (RANI) stock is trading at $3.78 as of 1:46 PM on Tuesday, Feb 6, a gain of $0.09, or 2.43% from the previous closing price of $3.69. The stock has traded between $3.70 and $3.80 so far today. Volume today is high. So far 125,406 shares have traded compared to average volume of 79,826 shares. To screen for more stocks like Rani Therapeutics Holdings Inc click here.

More About Rani Therapeutics Holdings Inc

Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. Click Here to get the full Stock Report for Rani Therapeutics Holdings Inc stock.